Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of a new affiliate, Neuraxpharm Australia, led by newly appointed Head of Commercial, Avendran Naidu, as the Company continues to expand globally..

Neuraxpharm集团（Neuraxpharm）是一家专注于中枢神经系统（CNS）疾病治疗的欧洲领先专业制药公司，宣布推出新的分支机构Neuraxpharm澳大利亚，由新任命的商务主管Avendran Naidu领导，公司继续推进全球扩张。

The launch of Neuraxpharm Australia continues the Company’s international growth strategy following the opening last year of Neuraxpharm Middle East and the establishment of affiliates in Brazil and Mexico in 2023. Neuraxpharm Australia will be based in Sydney and reflects Neuraxpharm’s intention to market its CNS products across Australia over the coming years..

Neuraxpharm澳大利亚公司的成立延续了公司去年开设Neuraxpharm中东公司以及2023年在巴西和墨西哥建立分支机构后的国际增长战略。Neuraxpharm澳大利亚公司将设在悉尼，表明Neuraxpharm计划在未来几年内将其中枢神经系统产品推广到整个澳大利亚市场。

Neuraxpharm Australia will commercialise the prescription brands Nuvigil® (armodafinil) and Modavigil® (modafinil), both indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy, which were acquired by Neuraxpharm in December 2024.

Neuraxpharm澳大利亚公司将商业化处方药品牌Nuvigil®（阿莫达非尼）和Modavigil®（莫达非尼），这两种药物均用于治疗成人嗜睡症患者的日间过度嗜睡（EDS），并于2024年12月由Neuraxpharm收购。

The Australian affiliate will also bring to market BRIUMVI® (ublituximab) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) after receiving approval from Australia’s Therapeutic Goods Administration (TGA) in June 2025.1 Following a positive recommendation by the Pharmaceutical Benefits Advisory Committee (PBAC) at its May 2025 meeting2, Neuraxpharm is now working to ensure eligible Australian patients can access BRIUMVI® as soon as possible..

澳大利亚分公司还将在2025年6月获得澳大利亚治疗用品管理局（TGA）批准后，将BRIUMVI®（乌比妥昔单抗）推向市场，用于治疗复发缓解型多发性硬化症（RRMS）的成年患者。在2025年5月的会议上，药品福利咨询委员会（PBAC）给出了积极的建议，Neuraxpharm现在正努力确保符合条件的澳大利亚患者能够尽快获得BRIUMVI®。

Ublituximab, developed by TG Therapeutics and licensed by Neuraxpharm ex-US3, is a novel anti-CD20 monoclonal antibody approved in the United States, the European Union, UK and Switzerland for the treatment of adult patients with RRMS that can be administered in a one-hour infusion, twice a year, following the starting dose.4,5 Additional leading CNS treatments from Neuraxpharm’s portfolio are expected to follow..

由TG Therapeutics开发、Neuraxpharm获得美国以外地区授权的Ublituximab，是一种新型抗CD20单克隆抗体，已在美国、欧盟、英国和瑞士获批用于治疗成年复发型多发性硬化症（RRMS）患者，可在初始剂量后每年两次、每次一小时输注。预计Neuraxpharm产品组合中的其他主要中枢神经系统治疗药物也将陆续跟进。

Neuraxpharm Australia will be led by Avendran Naidu, the affiliate’s newly appointed Head of Commercial. Avendran has more than 15 years of commercial sales and leadership experience in the pharmaceutical industry focusing on neuroscience, having worked on established and launched brands at companies including Jazz Pharmaceuticals ANZ (Australia & New Zealand), Teva Pharmaceuticals and Ferring Pharmaceuticals..

Neuraxpharm澳大利亚公司将由新任命的商务负责人艾文德兰·奈杜 (Avendran Naidu) 领导。艾文德兰在制药行业拥有超过15年的商业销售和领导经验，专注于神经科学领域，曾在包括Jazz Pharmaceuticals ANZ（澳大利亚和新西兰）、Teva Pharmaceuticals以及Ferring Pharmaceuticals等公司负责运营和推出知名品牌。

Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “Neuraxpharm’s launch in Australia reflects our successful ongoing global growth strategy, which is focused on providing a wide range of CNS treatments to patients in need. Australia is a key market for Neuraxpharm, and we welcome Avendran Naidu as a highly motivated and results-driven pharmaceutical commercial leader who will take Neuraxpharm Australia to the next level.

Neuraxpharm首席执行官Jörg-Thomas Dierks博士表示：“Neuraxpharm在澳大利亚的上市反映了我们持续推进的全球增长战略，该战略专注于为有需要的患者提供广泛的中枢神经系统（CNS）治疗方案。澳大利亚是Neuraxpharm的一个关键市场，我们欢迎Avendran Naidu作为一位充满动力且以结果为导向的医药商业领袖，他将带领Neuraxpharm澳大利亚迈向新的高度。”

We believe that our portfolio of products will be an important addition to the treatments currently available to Australian patients.”.

我们相信，我们的产品组合将为澳大利亚患者目前可用的治疗方案提供重要的补充。

Avendran Naidu, Head of Commercial for Neuraxpharm Australia, added: “This is an exciting time for Neuraxpharm Australia as we establish our presence in a new and important market. Our mission here is fully aligned with our global purpose: to provide innovative solutions for CNS disorders and improve the lives of patients.

Neuraxpharm澳大利亚商业主管阿文德兰·奈杜补充道：“这对Neuraxpharm澳大利亚来说是一个激动人心的时刻，因为我们正在一个崭新且重要的市场中确立自己的地位。我们的使命与全球目标完全一致：为中枢神经系统疾病提供创新解决方案，改善患者的生活。”

We are committed to making a meaningful impact in the Australian healthcare landscape. As we grow, we’ll be looking to build a team of passionate, like-minded professionals who share our dedication to advancing CNS care and improving patient outcomes.”.

我们致力于在澳大利亚医疗领域产生有意义的影响。随着我们的成长，我们将寻求建立一个充满热情、志同道合的专业团队，他们与我们一样，致力于推进中枢神经系统护理并改善患者预后。

Source: neuraxpharm.com

来源：neuraxpharm.com